WO2026126159 - CRYSTALLINE FORMS OF APROCITENTAN
National phase entry is expected:
Publication Number
WO/2026/126159
Publication Date
18.06.2026
International Application No.
PCT/IB2025/062792
International Filing Date
12.12.2025
Title **
[English]
CRYSTALLINE FORMS OF APROCITENTAN
[French]
FORMES CRISTALLINES DE L'APROCITENTAN
Applicants **
APITORIA PHARMA PRIVATE LIMITED
Inventors
NEELA, Praveen Kumar
ALI, Nasir
MUPPALLA, Siva Ramakrishna
MANDAD, Pratap Reddy
Priority Data
202441098992
13.12.2024
IN
Application details
| Total Number of Claims/PCT | * |
| Number of Independent Claims | * |
| Number of Priorities | * |
| Number of Multi-Dependent Claims | * |
| Number of Drawings | * |
| Pages for Publication | * |
| Number of Pages with Drawings | * |
| Pages of Specification | * |
| * | |
| Number of Office Actions | * |
| * | |
International Searching Authority |
IP India
* |
| Recordal of a Change of the Applicant's Name/Address |
Change of Applicant's Name and Address
* |
| Type of Assignment |
The Standard Agent's Assignment
* |
| Applicant's Legal Status |
Legal Entity
* |
| * | |
| * | |
| * | |
| * | |
| * | |
| Entry into National Phase under |
Chapter I
* |
| Patent Delivery |
Send the Letters Patent by Courier
* |
| Translation |
|
* The data is based on automatic recognition. Please verify and amend if necessary.
** IP-Coster compiles data from publicly available sources. If this data includes your personal information, you can contact us to request its removal.
Quotation for National Phase entry
| Country | Stages | Total | |
|---|---|---|---|
| China | Filing, Examination, Granting | 1955 | |
| EPO | Filing, Examination, Granting | 11624 | |
| Japan | Filing, Examination, Granting | 2015 | |
| South Korea | Filing, Examination, Granting | 1789 | |
| USA | Filing, Examination, Granting | 4740 |
Total:
22,123
Contact Us
Abstract[English]
The present invention relates to crystalline forms of Aprocitentan, processes for the preparation thereof, and pharmaceutical composition thereof.[French]
La présente invention concerne des formes cristallines de l'aprocitentan, des procédés pour leur préparation, ainsi que des compositions pharmaceutiques de celui-ci.